LXRX - Lexicon Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
The Woodlands,
United States
LXRX price evolution
LXRX
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $59.52 | $64.06 | $92.12 | $89.89 |
| Short term investments | $26.98 | $22.68 | $28.8 | $28.61 |
| Net receivables | $0.04 | $0.01 | $0.02 | $0.16 |
| Inventory | ||||
| Total current assets | $88.43 | $88.92 | $124 | $123.26 |
| Long term investments | ||||
| Property, plant & equipment | $1.14 | $1.18 | $1.31 | $1.2 |
| Goodwill & intangible assets | $44.54 | $44.54 | $44.54 | $44.54 |
| Total noncurrent assets | $47.75 | $47.99 | $48.33 | $48.41 |
| Total investments | $26.98 | $22.68 | $28.8 | $28.61 |
| Total assets | $136.18 | $136.91 | $172.33 | $171.67 |
| Current liabilities | ||||
| Accounts payable | $9.32 | $9.15 | $8.35 | $8.54 |
| Deferred revenue | ||||
| Short long term debt | $11.69 | $11.68 | ||
| Total current liabilities | $18.91 | $22.12 | $34.25 | $32.81 |
| Long term debt | $23.48 | |||
| Total noncurrent liabilities | $24.57 | $1.19 | $1.48 | $1.62 |
| Total debt | $23.48 | $11.69 | $11.68 | |
| Total liabilities | $43.48 | $23.31 | $35.73 | $34.44 |
| Shareholders' equity | ||||
| Retained earnings | -$1511.25 | -$1487.78 | -$1462.16 | -$1439.04 |
| Other shareholder equity | -$0.04 | -$0.01 | -$0.01 | -$0.01 |
| Total shareholder equity | $92.7 | $113.59 | $136.6 | $137.23 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $64.06 | $126.26 | $36.11 | $80.39 |
| Short term investments | $22.68 | $26.01 | $235.55 | $79.67 |
| Net receivables | $0.01 | $0.4 | $56.53 | $5.92 |
| Inventory | $4.24 | $4.68 | ||
| Total current assets | $88.92 | $157.72 | $337.75 | $173.32 |
| Long term investments | ||||
| Property, plant & equipment | $1.18 | $0.29 | $14.05 | $15.87 |
| Goodwill & intangible assets | $44.54 | $44.54 | $64.26 | $94.66 |
| Total noncurrent assets | $47.99 | $46.07 | $79.96 | $110.81 |
| Total investments | $22.68 | $26.01 | $235.55 | $79.67 |
| Total assets | $136.91 | $203.79 | $417.71 | $284.14 |
| Current liabilities | ||||
| Accounts payable | $9.15 | $5.47 | $12.18 | $17.76 |
| Deferred revenue | $27.05 | |||
| Short long term debt | $11.65 | $11.01 | $1.11 | |
| Total current liabilities | $22.12 | $46.81 | $65.34 | $36.75 |
| Long term debt | $234.17 | $243.89 | ||
| Total noncurrent liabilities | $1.19 | $0.61 | $235.27 | $273.79 |
| Total debt | $11.65 | $245.18 | $245 | |
| Total liabilities | $23.31 | $47.42 | $300.61 | $310.54 |
| Shareholders' equity | ||||
| Retained earnings | -$1487.78 | -$1400.02 | -$1341.44 | -$1471.58 |
| Other shareholder equity | -$0.01 | -$0.01 | $0.08 | -$0.01 |
| Total shareholder equity | $113.59 | $156.37 | $117.1 | -$26.41 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.04 | $0.01 | $0.02 | $0.23 |
| Cost of revenue | ||||
| Gross Profit | $0.04 | $0.01 | $0.02 | $0.23 |
| Operating activities | ||||
| Research & development | $14.93 | $16.5 | $15.68 | $10.26 |
| Selling, general & administrative | $8.49 | $8.85 | $7.3 | $7.94 |
| Total operating expenses | $23.42 | $25.34 | $22.98 | $18.19 |
| Operating income | -$23.38 | -$25.33 | -$22.96 | -$17.96 |
| Income from continuing operations | ||||
| EBIT | -$23.37 | -$25.32 | -$22.95 | -$17.9 |
| Income tax expense | ||||
| Interest expense | $0.11 | $0.29 | $0.17 | $0.17 |
| Net income | ||||
| Net income | -$23.48 | -$25.61 | -$23.12 | -$18.07 |
| Income (for common shares) | -$23.48 | -$25.61 | -$23.12 | -$18.07 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.3 | $24 | $322.07 | $63.21 |
| Cost of revenue | $1.93 | $3.23 | $2.49 | |
| Gross Profit | $0.3 | $22.07 | $318.84 | $60.72 |
| Operating activities | ||||
| Research & development | $55.05 | $153.62 | $91.92 | $100.24 |
| Selling, general & administrative | $32.34 | $47.23 | $56.84 | $63.75 |
| Total operating expenses | $87.39 | $69.87 | $177.4 | $164 |
| Operating income | -$87.09 | -$47.8 | $141.44 | -$103.28 |
| Income from continuing operations | ||||
| EBIT | -$86.96 | -$44.03 | $144.79 | -$99.77 |
| Income tax expense | -$6.01 | |||
| Interest expense | $0.8 | $14.54 | $20.68 | $20.78 |
| Net income | ||||
| Net income | -$87.76 | -$58.57 | $130.13 | -$120.55 |
| Income (for common shares) | -$87.76 | -$58.57 | $130.13 | -$120.55 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Net income | -$23.48 | -$25.61 | -$23.12 | -$18.07 |
| Operating activities | ||||
| Depreciation | $0.11 | $0.11 | $0.1 | $0.04 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.77 | $2.23 | $2.71 | $2.79 |
| Total cash flows from operations | -$23.42 | -$22.83 | -$17.15 | -$21.88 |
| Investing activities | ||||
| Capital expenditures | -$0.08 | -$0.02 | -$0.21 | -$0.95 |
| Investments | -$4.33 | $6.12 | -$0.19 | $15.09 |
| Total cash flows from investing | -$4.41 | $6.1 | -$0.4 | $14.14 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.86 | $0.38 | $19.78 | -$0.02 |
| Net borrowings | $24.15 | -$11.7 | ||
| Total cash flows from financing | $23.28 | -$11.32 | $19.78 | -$0.02 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4.54 | -$28.05 | $2.23 | -$7.76 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$87.76 | -$58.57 | $130.13 | -$120.55 |
| Operating activities | ||||
| Depreciation | $0.29 | $2.93 | $3.65 | $3.68 |
| Business acquisitions & disposals | $160.38 | |||
| Stock-based compensation | $10.58 | $13.27 | $14.22 | $11.7 |
| Total cash flows from operations | -$87.02 | -$142.97 | $113.81 | -$148.61 |
| Investing activities | ||||
| Capital expenditures | -$1.22 | $10.93 | -$0.07 | -$0.1 |
| Investments | $3.33 | $209.44 | -$155.78 | $169.67 |
| Total cash flows from investing | $2.11 | $380.76 | -$155.85 | $169.58 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $34.41 | $68.94 | -$0.94 | -$0.24 |
| Net borrowings | -$11.7 | -$216.58 | -$1.28 | -$2 |
| Total cash flows from financing | $22.71 | -$147.64 | -$2.23 | -$2.24 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$62.2 | $90.15 | -$44.27 | $18.73 |
News
|
Lexicon Says Drug Reduced Major Cardiovascular Events in Trial
Bloomberg
2 Apr 2022
|
|
Lexicon Announces Loan Facility Of $150M With Oxford Finance To Support Sotagliflozin...
Benzinga via Yahoo Finance
18 Mar 2022
|
|
The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon...
Zacks via Yahoo Finance
4 Mar 2022
|
|
67 Biggest Movers From Yesterday
Benzinga
1 Mar 2022
|
|
Lexicon: Q4 Earnings Snapshot
The Fairfield Citizen
28 Feb 2022
|
|
U.S. stocks lower at close of trade; Dow Jones Industrial Average unchanged By Investing.com
Investing.com
28 Feb 2022
|
|
27 Stocks Moving in Monday's Pre-Market Session
Benzinga
28 Feb 2022
|
|
Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug
Entrpreneur
3 Jan 2022
|
|
21 Stocks Moving In Friday's Mid-Day Session
Benzinga
31 Dec 2021
|
|
81 Biggest Movers From Yesterday
Benzinga
5 Nov 2021
|
Fundamentals
| Market cap | $290.20M |
|---|---|
| Enterprise value | $254.16M |
| Shares outstanding | 149.59M |
| Revenue | $308.00K |
|---|---|
| EBITDA | -$89.17M |
| EBIT | -$89.53M |
| Net Income | -$90.28M |
| Revenue Q/Q | 37.04% |
| Revenue Y/Y | -98.08% |
| P/E ratio | -3.21 |
|---|---|
| EV/Sales | 825.20 |
| EV/EBITDA | -2.85 |
| EV/EBIT | -2.84 |
| P/S ratio | 942.22 |
| P/B ratio | 3.13 |
| Book/Share | 0.62 |
| Cash/Share | 0.40 |
| EPS | -$0.60 |
|---|---|
| ROA | -58.52% |
| ROE | -75.21% |
| Debt/Equity | 0.21 |
|---|---|
| Net debt/EBITDA | 0.18 |
| Current ratio | 4.68 |
| Quick ratio | 4.68 |